Xiao Xuan Xing1,2, Chen Zhu3, Hua Yu Liang4, Ke Wang1,2, Yan Qi Chu1,2, Li Bo Zhao5, De Chun Jiang1,2, Yu Qin Wang1,2, Su Ying Yan1,2. 1. 1 Xuanwu Hospital of Capital Medical University, Beijing, P R China. 2. 2 National Clinical Research Center for Geriatric Disorders, Beijing, P R China. 3. 3 Zhejiang University, Hangzhou, P R China. 4. 4 The Seventh Medical Center of PLA General Hospital, Beijing, P R China. 5. 5 Capital Medical University, Beijing, P R China.
Abstract
Background: Adverse drug outcomes in the elderly have led to the development of lists of potentially inappropriate medications (PIMs), such as the Beers criteria, and these PIMs have been studied widely; however, it is still unclear whether PIM use is predictive of adverse outcomes in older people. Objective: To qualitatively examine the associations between exposure to PIMs from the general Beers criteria and the Screening Tool of Older Persons' Prescriptions list and adverse outcomes, such as adverse drug reactions (ADRs)/adverse drug events (ADEs), hospitalization, and mortality. Methods: Specified databases were searched from inception to February 1, 2018. Two reviewers independently selected studies that met the inclusion criteria, assessed study quality, and extracted data. Data were pooled using Stata 12.0. The outcomes were ADRs/ADEs, hospitalization, and mortality. Results: A total of 33 studies met the inclusion criteria. The combined analysis revealed a statistically significant association between ADRs/hospitalizations and PIMs (odds ratio [OR] = 1.44, 95% CI = 1.33-1.56; OR = 1.27, 95% CI = 1.20-1.35), but no statistically significant association was found between mortality and PIMs (OR = 1.04; 95% CI = 0.75-1.45). It is interesting to note that the results changed when different continents/criteria were used for the analysis. Compared with the elderly individuals exposed to 1 PIM, the risk of adverse health outcomes was much higher for those who took ≥2 PIMs. Conclusion and Relevance: We recommend that clinicians avoid prescribing PIMs for older adults whenever feasible. In addition, the observed associations should be generalized to other countries with different PIM criteria with caution.
Background: Adverse drug outcomes in the elderly have led to the development of lists of potentially inappropriate medications (PIMs), such as the Beers criteria, and these PIMs have been studied widely; however, it is still unclear whether PIM use is predictive of adverse outcomes in older people. Objective: To qualitatively examine the associations between exposure to PIMs from the general Beers criteria and the Screening Tool of Older Persons' Prescriptions list and adverse outcomes, such as adverse drug reactions (ADRs)/adverse drug events (ADEs), hospitalization, and mortality. Methods: Specified databases were searched from inception to February 1, 2018. Two reviewers independently selected studies that met the inclusion criteria, assessed study quality, and extracted data. Data were pooled using Stata 12.0. The outcomes were ADRs/ADEs, hospitalization, and mortality. Results: A total of 33 studies met the inclusion criteria. The combined analysis revealed a statistically significant association between ADRs/hospitalizations and PIMs (odds ratio [OR] = 1.44, 95% CI = 1.33-1.56; OR = 1.27, 95% CI = 1.20-1.35), but no statistically significant association was found between mortality and PIMs (OR = 1.04; 95% CI = 0.75-1.45). It is interesting to note that the results changed when different continents/criteria were used for the analysis. Compared with the elderly individuals exposed to 1 PIM, the risk of adverse health outcomes was much higher for those who took ≥2 PIMs. Conclusion and Relevance: We recommend that clinicians avoid prescribing PIMs for older adults whenever feasible. In addition, the observed associations should be generalized to other countries with different PIM criteria with caution.
Authors: Jessica E Lockery; Michael E Ernst; Jonathan C Broder; Suzanne G Orchard; Anne Murray; Mark R Nelson; Nigel P Stocks; Rory Wolfe; Christopher M Reid; Danny Liew; Robyn L Woods Journal: Pharmacotherapy Date: 2020-10 Impact factor: 4.705
Authors: Marcelo Schapira; Pablo Calabró; Manuel Montero-Odasso; Abdelhady Osman; María Elena Guajardo; Bernardo Martínez; Javier Pollán; Luis Cámera; Miguel Sassano; Gastón Perman Journal: Aging Clin Exp Res Date: 2020-05-09 Impact factor: 3.636
Authors: Akshaya S Bhagavathula; Kota Vidyasagar; Manik Chhabra; Muhammed Rashid; Rishabh Sharma; Deepak K Bandari; Daniela Fialova Journal: Front Pharmacol Date: 2021-05-19 Impact factor: 5.810
Authors: Sam Kosari; Jane Koerner; Mark Naunton; Gregory M Peterson; Ibrahim Haider; Emily Lancsar; David Wright; Theo Niyonsenga; Rachel Davey Journal: Trials Date: 2021-06-11 Impact factor: 2.279